Fate of aortic bioprostheses: An 18-year experience

Slides:

Advertisements

Similar presentations

Tubular heart valves: A new tissue prosthesis design—Preclinical evaluation of the 3F aortic bioprosthesis James L. Cox, MD, Niv Ad, MD, Keith Myers, BS,

Advertisements

W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P

Transcatheter aortic valve replacement in patients with severe aortic stenosis who are at high risk for surgical complications: Summary assessment of.

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Of mice and men and surgical transcatheter aortic valve insertion

The fate of small-size pericardial heart valve prostheses in an older patient population Ruggero De Paulis, MD, Salvatore D'Aleo, MD, Alessandro Bellisario,

Aortic valve replacement in low-flow, low-gradient aortic stenosis: Left ventricular ejection fraction matters Victor Dayan, MD, PhD, Philippe Pibarot,

Influence of the On-X mechanical prosthesis on intermediate-term major thromboembolism and hemorrhage: A prospective multicenter study Vincent Chan,

Paravalvular regurgitation after conventional aortic and mitral valve replacement: A benchmark for alternative approaches Brett F. Duncan, MD, Patrick.

An unusual case of severe aortic valve stenosis in an adult caused by aortic valve inflammatory myofibroblastic tumor Dong Zhao, MD, Chunsheng Wang,

Scott Goldman, MD, Anson Cheung, MD, Joseph E. Bavaria, MD, Michael R

Lars G. Svensson, MD, PhD, Lillian H. Batizy, MS, Eugene H

Management of concomitant mild to moderate functional mitral regurgitation during aortic valve surgery for severe aortic insufficiency Ju Yong Lim, MD,

Harald C. Eichstaedt, MD, Jerry Easo, MD, Tobias Härle, MD, Otto E

When is the Ross operation a good option to treat aortic valve disease? Tirone E. David, MD, Anna Woo, MD, Susan Armstrong, MSc, Manjula Maganti, MSc

Transapical transcatheter aortic valve-in-valve implantation: Clinical and hemodynamic outcomes beyond 2 years Jian Ye, MD, FRCSC, John G. Webb, MD,

Long-term follow-up after aortic valve replacement with Edwards Prima Plus stentless bioprostheses in patients younger than 60 years of age Torsten Christ,

The fate of small-size pericardial heart valve prostheses in an older patient population Ruggero De Paulis, MD, Salvatore D'Aleo, MD, Alessandro Bellisario,

Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: Weighing lifetime anticoagulant-related event risk against.

Reoperative “valve-in-valve” transapical transcatheter mitral valve replacement in a high-risk patient with a recent transapical transcatheter aortic.

Hassane Abdallah, MD, Alaae Boutayeb, MD, Gebrine El Khoury, PhD

It is still mostly about the mitral valve

Biventricular repair in patients with heterotaxy syndrome

Bicuspid aortic valve aortopathy: One size fits all?

Long-term results of aortic valve–sparing operations in patients with Marfan syndrome Tirone E. David, MD, Sue Armstrong, BSc, Manjula Maganti, BSc, Jack.

Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement Ole Lund, MD, PhD, Martin Bland,

Antimineralization treatment and patient-prosthesis mismatch are major determinants of the onset and incidence of structural valve degeneration in bioprosthetic.

Long-term evaluation of biological versus mechanical prosthesis use at reoperative aortic valve replacement Vincent Chan, MD, MPH, B-Khanh Lam, MD, MPH,

A near 100% repair rate for mitral valve prolapse is achievable in a reference center: Implications for future guidelines Javier G. Castillo, MD, Anelechi.

W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P

Transcatheter aortic valve replacement in intermediate-risk patients

Structural deterioration of the Freestyle aortic valve: Mode of presentation and mechanisms Siamak Mohammadi, MD, Richard Baillot, MD, Pierre Voisine,

Aortic valve replacement with the Mitroflow pericardial bioprosthesis: Durability results up to 21 years Charles A. Yankah, MD, PhD, Miralem Pasic, MD,

Michele Gallo, MD, Gino Gerosa, MD

Stentless biological valved conduit for aortic root replacement: Initial experience with the Shelhigh BioConduit model NR-2000C Abdullah Kaya, MD, Robin.

Laurens W. Wollersheim, MD, Wilson W

Effect of the prosthesis–patient mismatch on long-term clinical outcomes after isolated aortic valve replacement for aortic stenosis: A prospective observational.

The aortic valve–sparing operation

Transcatheter aortic valve replacement and surgical aortic valve replacement: Both excellent therapies J. James Edelman, MBBS(Hons), PhD, Vinod H. Thourani,

Midterm results of Manouguian double valve replacement: Comparison with standard double valve replacement Hiroshi Okuyama, MD, Kazuhiro Hashimoto, MD,

Chronic obstructive pulmonary disease severity influences outcomes after off-pump coronary artery bypass Benjamin Medalion, MD, Michael G. Katz, MD,

Tirone E. David, MD, Gheorghe Gavra, MD, Christopher M

Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD

David valve-sparing aortic root replacement: Equivalent mid-term outcome for different valve types with or without connective tissue disorder John-Peder.

Replicating the success of mitral valve repair in the aortic valve

Bradley G. Leshnower, MD, Robert A. Guyton, MD, Richard J

Marc Licker, MD, John Diaper, RA

Thirty-year experience with a bileaflet mechanical valve prosthesis

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Sutureless valve implantation: Every detail counts

The Mitroflow aortic valve: A past, present, and future illuminated

Hans-Joachim Schäfers, MD

Transcatheter aortic valve replacement for prime time unrestricted distribution? Not so fast, my friend G. Michael Deeb, MD, John Carroll, MD The Journal.

Concomitant replacement of the ascending aorta is free—for some

Long-term results of Freestyle stentless bioprosthesis in the aortic position: A single- center prospective cohort of 500 patients Nicolas Amabile, MD,

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Permanent pacemaker insertion following transcatheter aortic valve replacement: Not infrequent, not benign, and becoming predictable Craig M. Jarrett,

Long-term results of the Medtronic Mosaic porcine bioprosthesis in the aortic position Amedeo Anselmi, MD, Erwan Flécher, MD, PhD, Vito Giovanni Ruggieri,

“The more things change…”: The challenges ahead

Toward a more rational approach in treating type B aortic dissection

Valve-sparing aortic root replacement in bicuspid aortic valves: A reasonable option? Diana Aicher, MD, Frank Langer, MD, Anke Kissinger, Henning Lausberg,

Respect the aorta The Journal of Thoracic and Cardiovascular Surgery

Chordal replacement with polytetrafluoroethylene sutures for mitral valve repair: A 25- year experience Tirone E. David, MD, Susan Armstrong, MSc, Joan.

Which biologic valve should we select for the 45- to 65-year-old age group requiring aortic valve replacement? F. Dagenais, MD, P. Cartier, MD, P. Voisine,

Thanos Sioris, MD, Tirone E

Descending thoracic and thoracoabdominal aortic aneurysms: “Busted”

Zone zero thoracic endovascular aortic repair is all about “location, location, location” Kevin L. Greason, MD The Journal of Thoracic and Cardiovascular.

Fate of functional tricuspid regurgitation in aortic stenosis after aortic valve replacement Dong Seop Jeong, MD, PhD, Kiick Sung, MD, PhD, Wook Sung.

Presentation transcript:

Fate of aortic bioprostheses: An 18-year experience Alessandro Piccardo, MD, Jean David Blossier, MD, Alexandre Le Guyader, MD, Isabelle Orsel, MD, Seifeddine Sekkal, MD, Elisabeth Cornu, MD, Marc Laskar, MD The Journal of Thoracic and Cardiovascular Surgery Volume 151, Issue 3, Pages 754-761.e1 (March 2016) DOI: 10.1016/j.jtcvs.2015.10.020 Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Overall survival after aortic valve replacement with the Mitroflow (Sorin, Vancouver, Canada) aortic bioprosthesis, showing nonemergent isolated aortic valve replacement (black line) and the overall population (red line). The Journal of Thoracic and Cardiovascular Surgery 2016 151, 754-761.e1DOI: (10.1016/j.jtcvs.2015.10.020) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Freedom from reintervention for structural valve deterioration after aortic valve replacement with Mitroflow (Sorin, Vancouver, Canada) aortic bioprosthesis. SVD, Structural valve deterioration. The Journal of Thoracic and Cardiovascular Surgery 2016 151, 754-761.e1DOI: (10.1016/j.jtcvs.2015.10.020) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Freedom from reoperation for endocarditis on operated valve after aortic valve replacement with Mitroflow (Sorin, Vancouver, Canada) aortic bioprosthesis. The Journal of Thoracic and Cardiovascular Surgery 2016 151, 754-761.e1DOI: (10.1016/j.jtcvs.2015.10.020) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 Freedom from echocardiographic signs of structural valve deterioration (SVD) (ie, mean transprosthetic gradient >40 mm Hg or aortic regurgitation greater than mild) after aortic valve replacement with Mitroflow (Sorin, Vancouver, Canada) aortic bioprosthesis. The Journal of Thoracic and Cardiovascular Surgery 2016 151, 754-761.e1DOI: (10.1016/j.jtcvs.2015.10.020) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 5 Freedom from echocardiographic signs of structural valve deterioration (SVD) (ie, mean transprosthetic gradient >40 mm Hg or aortic regurgitation greater than mild) after aortic valve replacement with Mitroflow (Sorin, Vancouver, Canada) aortic bioprosthesis, according to severe (black line), moderate (blue line), or no (red line) patient–prosthesis mismatch. The Journal of Thoracic and Cardiovascular Surgery 2016 151, 754-761.e1DOI: (10.1016/j.jtcvs.2015.10.020) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 6 Freedom from echocardiographic signs of structural valve deterioration (SVD) (ie, mean transprosthetic gradient >40 mm Hg or aortic regurgitation greater than mild) after aortic valve replacement with Mitroflow (Sorin, Vancouver, Canada) aortic bioprosthesis, according to prosthesis size 19 (blue line) or size >19 (red line). The Journal of Thoracic and Cardiovascular Surgery 2016 151, 754-761.e1DOI: (10.1016/j.jtcvs.2015.10.020) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Freedom from structural valve deterioration (SVD) according to size of prosthesis. The Journal of Thoracic and Cardiovascular Surgery 2016 151, 754-761.e1DOI: (10.1016/j.jtcvs.2015.10.020) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions